Pharma Compliance Risk Assessment Framework

Published by Eunomia Pharma Services · Updated 1 October 2026

How do you build a practical pharma compliance risk assessment?

Begin with the company’s actual activities, markets and third parties. Describe what could go wrong, assess the exposure and existing controls, then prioritise gaps with named owners and completion dates. Review the assessment when activities or risks change. A useful risk register explains decisions and drives action; a score alone does not show that a risk is controlled.

A practical starting structure for your risk register

Activity and exposure: record the process, country, stakeholders and a specific risk scenario.
Existing controls and evidence: identify the control owner and evidence that the control operates in practice.
Priority and response: explain the likelihood and impact assessment, remaining exposure and proposed action.
Follow-up: assign an accountable owner, target date and a check to establish whether the action worked.

The practical steps above are Eunomia’s operational guidance. See the source notes below for the scope of the external references.

In today's pharmaceutical industry, compliance risk assessment is no longer just a regulatory requirement—it's a strategic business capability. An effective framework protects your organisation's reputation, strengthens governance, supports sustainable growth, and builds trust with regulators, healthcare professionals (HCPs), and patients.

For many small and mid-sized pharmaceutical companies, limited resources, evolving regulations, and increasing operational complexity make compliance challenging. The solution is not to create increasingly complex compliance programmes, but to implement a practical, risk –based framework that becomes part of everyday business operations.

Focus on Your Highest-Risk Activities

Start by identifying the processes that pose the greatest compliance risk, including:

Healthcare Professional (HCP) Engagements
Promotional Material Review & Approval
Transparency Reporting
Fair Market Value (FMV) Assessments
Third-Party Due Diligence
Data Privacy & Protection
Local Regulatory Requirements
Grants, donations and sponsorship activities
Medical information and scientific exchange

Prioritising high-risk areas enables organisations to focus resources where they have the greatest impact.

Make Risk Assessment a Continuous Process

Compliance risks evolve with new products, market expansion, digital engagement, and changing regulations. Moving beyond annual assessments to continuous monitoring helps organisations remain proactive, audit-ready, and resilient.

Build Governance into Everyday Operations

Strong governance is the foundation of effective compliance. Standard Operating Procedures (SOPs), clearly defined roles, structured approval workflows, and consistent documentation reduce risk, improve decision-making, and drive operational consistency.

Use Technology to Strengthen Compliance

Manual spreadsheets and fragmented processes create unnecessary risk. Technology-enabled workflows, centralised documentation, automated approvals, and real-time dashboards improve visibility, increase reporting accuracy, and support better compliance outcomes.

Compliance Is a Business Advantage

Leading pharmaceutical companies don't view compliance risk assessment as a regulatory obligation—they see it as a business enabler. Embedding risk management into everyday operations improves efficiency, strengthens governance, reduces compliance risk, and supports confident business growth.

How Eunomia Pharma Services Can Help

At Eunomia Pharma Services, we help pharmaceutical and biotechnology companies build practical, scalable compliance risk assessment frameworks tailored to their business. From HCP engagement governance and promotional review to transparency reporting, third-party due diligence, and governance frameworks, we help organisations identify risks early, strengthen controls, and maintain audit-ready compliance.

Effective compliance starts with understanding your risks. Sustainable growth starts with managing them.

How do inherent risk, residual risk and a control gap differ?

Use these terms consistently before assigning scores. Otherwise, two teams can give the same activity different ratings simply because one assumes controls work and the other ignores them. The distinctions below are a suggested working method, not a prescribed scoring system.

Practical comparison: How do inherent risk, residual risk and a control gap differ
Assessment	Question to answer	Evidence to record
Inherent risk	What could happen before considering controls?	Activity, affected stakeholders, likelihood and potential impact.
Control effectiveness	Does the control operate as intended?	A recent sample, named owner and evidence of exceptions.
Residual risk	What exposure remains after the controls?	A reasoned rating and any uncertainty about the evidence.
Control gap	What needs to change?	Action, accountable owner, deadline and effectiveness check.

How would this work for an HCP engagement?

Consider an illustrative engagement approved after the work has begun. The issue is not simply an incomplete form: the company may have committed to a service before checking its purpose, fee and approvals. Trace the request, agreement and payment through the process. Establish whether the problem was unclear ownership, a bypassed system step or a genuine emergency route. Agree a response that addresses the cause and test a later sample. A new procedure alone does not establish that the gap has closed.

Discuss a pharmaceutical compliance risk assessment.

Sources and scope

Ministry of Justice: Bribery Act 2010 guidance
UK guidance on proportionate bribery-prevention procedures; it is not a universal healthcare compliance checklist.

External sources accessed 28 September 2026. Check the applicable country rules and current source text for a specific engagement.

How Small and Mid-Sized Pharma Companies Can Build an Effective Compliance Risk Assessment Framework